A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Anna Berkenblit, MD
AVEO Pharmaceuticals, Inc.
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
49 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Facility name not stated
Hamilton, Ontario, Canada
- Facility name not stated
Toronto, Ontario, Canada
- Facility name not stated
Montreal, Quebec, Canada
- Aveo Investigational Site
Madurai, India
- Aveo Investigational Site
Mumbai, India
- Facility name not stated
Rotterdam, Netherlands
- Aveo Investigational Site
Krasnodar, Russia
- Aveo Investigational Site - Moscow 1
Moscow, Russia
- Aveo Investigational Site - Moscow 2
Moscow, Russia
- Aveo Investigational Site - Moscow 3
Moscow, Russia
- Aveo Investigational Site - Moscow 4
Moscow, Russia
- Aveo Investigational Site - Moscow 5
Moscow, Russia
- Aveo Investigational Site
Obninsk, Russia
- Aveo Investigational Site
Rostov-on-Don, Russia
- Aveo Investigational Site
Saint Petersburg, Russia
- Facility name not stated
Stavropol, Russia
- Aveo Investigational Site
Ufa, Russia
- Aveo Investigational Site
Dnipropetrovsk, Ukraine
- Aveo Investigational Site
Donetsk, Ukraine
- Aveo Investigational Site
Kharkiv, Ukraine
- Aveo Investigational Site
Lviv, Ukraine
- Aveo Investigational Site
Zaporizhya, Ukraine
- Translational Genomics Research Institute (tgen)
Scottsdale, Arizona, United States
- Institute of Urologic Oncology
Los Angeles, California, United States
- Stanford University
Stanford, California, United States
- Facility name not stated
Aurora, Colorado, United States
- Florida Cancer Specialists
Fort Myers, Florida, United States
- H. Lee Moffitt Cancer Center & Research Institute Hospital, Inc
Tampa, Florida, United States
- Facility name not stated
Beech Grove, Indiana, United States
- Horizon Oncology Research, Inc.
Lafayette, Indiana, United States
- Facility name not stated
Wichita, Kansas, United States
- Medical Oncology Llc
Baton Rouge, Louisiana, United States
- Jayne Gurtler Md, Laura Brinz Md, Angelo Russo Md and Janet Burroff Md Apmc
Metairie, Louisiana, United States
- Associates in Oncology/hematology
Rockville, Maryland, United States
- Dana Farber Cancer Institute
Boston, Massachusetts, United States
- Facility name not stated
Grand Rapids, Michigan, United States
- Facility name not stated
Tupelo, Mississippi, United States
- Nebraska Methodist Hospital
Omaha, Nebraska, United States
- Facility name not stated
Las Vegas, Nevada, United States
- Facility name not stated
Lebanon, New Hampshire, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Jun 2010
- Primary completion
- 30 Jun 2015
- Completion
- 31 Oct 2015
- Last update posted
- 1 Sept 2020
- Registered enrollment
- 225
- Registry id
- NCT01369433
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.